Headline News

 

AstraZeneca’s Datopotamab deruxtecan receives priority review for patients with previously treated advanced EGFR-mutated non-small cell lung cancer in the U.S.

Posted on January 13, 2025

Sasanlimab in combination with BCG improves event-free survival in patients with BCG-Naïve, high-risk Non-Muscle Invasive Bladder Cancer

Posted on January 13, 2025

Sanofi’s Sarclisa subcutaneous formulation meets co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma

Posted on January 13, 2025

Sarclisa receives first approval for the treatment of adult patients with relapsed or refractory multiple myeloma

Posted on January 13, 2025

Novartis Phase III study meets primary endpoint in children and young adults with SMA

Posted on January 06, 2025

VYDURA with ENHANZE receives regulatory approval for Chronic Inflammatory Demyelinating Polyneuropathy

Posted on January 06, 2025

Takeda receives regulatory approval for HYQVIA 10% subcutaneous injection set with ENHANZE for patients with Agammaglobulinemia

Posted on January 06, 2025

RYBREVANT approved in combination with LAZCLUZE for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer

Posted on January 06, 2025

Neumora Therapeutics releases new data from KOASTAL-1 Study of Navacaprant in major depressive disorder

Posted on January 03, 2025

TEVIMBRA approved for the treatment of gastric and gastroesophageal junction cancers in combination with chemotherapy

Posted on January 03, 2025

GSK’s Nucala receives approval for the treatment of Chronic rhinosinusitis with nasal polyps in China

Posted on January 03, 2025

Lynparza OlympiA Phase III trial demonstrates clinically meaningful survival benefits in early breast cancer

Posted on December 30, 2024

Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoints

Posted on December 30, 2024

Takeda announces approval of HYQVIA® 10% S.C. Injection for patients with Agammaglobulinemia or Hypogammaglobulinemia

Posted on December 30, 2024

Johnson & Johnson set to license novel oral assets strengthening commitment to atopic dermatitis

Posted on December 30, 2024